Subscribe to our newsletter.
Copyright 2024 © All rights Reserved Goffin Molecular Technologies
EGFR mutations drive cancers like lung and breast cancer. The SensID EGFR-Multiplex product includes TKI-sensitive and TKI-resistant mutations, relevant for Non-Small Cell Lung Cancer (NSCLC) therapy. It can be used for diagnostics and validation in liquid biopsy assays or developing EGFR diagnostic kits.
The set includes highly characterized cfDNA from cell lines and comes with 0%, 0.1%, 1%, and 5% allelic frequency standards.These products are also ideal for digital PCR and Next Generation Sequencing (NGS), supporting the validation of sequencing (e.g., WGS, Amplicon Sequencing) and PCR protocols, as well as determining detection limits.
Instruction for Use
EGFR mutations play a key role in driving the development of cancers such as lung and breast cancer. The mutations included in the SensID EGFR-Multiplex product feature a combination of both TKI-sensitive and TKI-resistant variations, which are crucial for treating Non-Small Cell Lung Cancer (NSCLC).
The EGFR-Multiplex Set cfDNA product is designed for use in diagnostics, offering an allelic frequency standard range for liquid biopsy assays in laboratory or research and development settings. It is also suitable for the validation and creation of EGFR diagnostic kits. The material provided consists of well-characterized human cfDNA derived from cell lines. The set includes individual components (SID-0003, SID-000015, SID-000017, and SID-000019) and supports the validation of internal processes, both qualitatively and quantitatively, at 0%, 0.1%, 1%, and 5% allelic frequency levels.
This product is ready to use.
Subscribe to our newsletter.